{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,31]],"date-time":"2026-10-31T23:15:08Z","timestamp":1793488508217,"version":"4.5.0"},"reference-count":14,"publisher":"Wiley","issue":"4","license":[{"start":{"date-parts":[[2018,2,22]],"date-time":"2018-02-22T00:00:00Z","timestamp":1519257600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000049","name":"National Institute on Aging","doi-asserted-by":"publisher","award":["R01\u2010AG\u2010034676"],"award-info":[{"award-number":["R01\u2010AG\u2010034676"]}],"id":[{"id":"10.13039\/100000049","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006108","name":"National Center for Advancing Translational Sciences","doi-asserted-by":"publisher","award":["UL1\u2010TR\u2010000135"],"award-info":[{"award-number":["UL1\u2010TR\u2010000135"]}],"id":[{"id":"10.13039\/100006108","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Arthritis Care &amp; Research"],"published-print":{"date-parts":[[2018,4]]},"abstract":"Objective<\/jats:title>To investigate the use of glucocorticoids (GC<\/jats:styled-content>s) and related adverse events (AE<\/jats:styled-content>s) in a long\u2010term, geographically defined cohort of patients with polymyalgia rheumatica (PMR<\/jats:styled-content>).<\/jats:p><\/jats:sec>Methods<\/jats:title>Using a population\u2010based inception cohort, details of GC<\/jats:styled-content> therapy were abstracted from medical records of all patients diagnosed with PMR<\/jats:styled-content> in 2000\u20132014. Age\u2010 and sex\u2010matched comparators without PMR<\/jats:styled-content> were identified from the same underlying population. Cumulative and daily dosage of GC<\/jats:styled-content>, rate of disease relapse, occurrence of GC<\/jats:styled-content>\u2010related AE<\/jats:styled-content>s, and rate of GC<\/jats:styled-content> discontinuation were analyzed.<\/jats:p><\/jats:sec>Results<\/jats:title>The study included 359 patients with PMR<\/jats:styled-content> and 359 comparators. The median time to taper below 5 mg\/day for 6 months was 1.44 years (95% confidence interval [95% CI<\/jats:styled-content>] 1.36\u20131.62), while the median time to permanent discontinuation was 5.95 years (95% CI<\/jats:styled-content> 3.37\u20138.88). The mean \u00b1 SD<\/jats:styled-content> cumulative dose of GC<\/jats:styled-content> at 2 and 5 years was 4.0 \u00b1 3.5 grams and 6.3 \u00b1 9.8 grams, respectively. The mean \u00b1 SD<\/jats:styled-content> daily dose of GC<\/jats:styled-content> at 2 and 5 years was 6.1 \u00b1 7.6 mg\/day and 7.2 \u00b1 9.5 mg\/day, respectively. There were no differences in rates of AE<\/jats:styled-content>s between patients with PMR<\/jats:styled-content> and comparators for diabetes mellitus, hypertension, hyperlipidemia, or hip, vertebral, or Colles fractures (P<\/jats:italic> > 0.2 for all). Cataracts were more common in patients with PMR<\/jats:styled-content> than comparators (hazard ratio 1.72 [95% CI<\/jats:styled-content> 1.23\u20132.41]).<\/jats:p><\/jats:sec>Conclusion<\/jats:title>Relapse rates in PMR<\/jats:styled-content> are highest in the early stages of therapy. Despite often protracted therapy, with the exception of cataracts, the rates of studied morbidities linked to GC<\/jats:styled-content> are not more common in PMR<\/jats:styled-content> than comparators.<\/jats:p><\/jats:sec>","DOI":"10.1002\/acr.23320","type":"journal-article","created":{"date-parts":[[2017,7,13]],"date-time":"2017-07-13T16:02:39Z","timestamp":1499961759000},"page":"643-647","source":"Crossref","is-referenced-by-count":49,"title":["Comparable Rates of Glucocorticoid\u2010Associated Adverse Events in Patients With Polymyalgia Rheumatica and Comorbidities in the General Population"],"prefix":"10.1002","volume":"70","author":[{"given":"Izzat","family":"Shbeeb","sequence":"first","affiliation":[{"name":"Mayo Clinic College of Medicine Rochester Minnesota"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Divya","family":"Challah","sequence":"additional","affiliation":[{"name":"Mayo Clinic College of Medicine Rochester Minnesota"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shafay","family":"Raheel","sequence":"additional","affiliation":[{"name":"Mayo Clinic College of Medicine Rochester Minnesota"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cynthia S.","family":"Crowson","sequence":"additional","affiliation":[{"name":"Mayo Clinic College of Medicine Rochester Minnesota"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric L.","family":"Matteson","sequence":"additional","affiliation":[{"name":"Mayo Clinic College of Medicine Rochester Minnesota"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2018,2,22]]},"reference":[{"key":"e_1_2_6_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.rdc.2015.08.009"},{"key":"e_1_2_6_3_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11926-015-0513-4"},{"key":"e_1_2_6_4_1","first-page":"1547","article-title":"Polymyalgia rheumatica and giant cell arteritis","volume":"74","author":"Unwin B","year":"2006","journal-title":"Am Fam Physician"},{"key":"e_1_2_6_5_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.34356"},{"key":"e_1_2_6_6_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.23338"},{"key":"e_1_2_6_7_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2016.5444"},{"key":"e_1_2_6_8_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2015-207578"},{"key":"e_1_2_6_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.mayocp.2012.08.012"},{"key":"e_1_2_6_10_1","doi-asserted-by":"publisher","DOI":"10.1002\/acr.23132"},{"key":"e_1_2_6_11_1","first-page":"S86","article-title":"Discontinuation of therapies in polymyalgia rheumatica and giant cell arteritis","volume":"31","author":"Muratore F","year":"2013","journal-title":"Clin Exp Rheumatol"},{"key":"e_1_2_6_12_1","doi-asserted-by":"publisher","DOI":"10.1136\/ard.52.12.847"},{"key":"e_1_2_6_13_1","doi-asserted-by":"publisher","DOI":"10.1503\/cmaj.140266"},{"key":"e_1_2_6_14_1","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.110851"},{"key":"e_1_2_6_15_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.39333"}],"container-title":["Arthritis Care & Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Facr.23320","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/acrjournals.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/acr.23320","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T15:09:03Z","timestamp":1759417743000},"score":1,"resource":{"primary":{"URL":"https:\/\/acrjournals.onlinelibrary.wiley.com\/doi\/10.1002\/acr.23320"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,2,22]]},"references-count":14,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2018,4]]}},"alternative-id":["10.1002\/acr.23320"],"URL":"https:\/\/doi.org\/10.1002\/acr.23320","archive":["Portico"],"relation":{},"ISSN":["2151-464X","2151-4658"],"issn-type":[{"value":"2151-464X","type":"print"},{"value":"2151-4658","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,2,22]]}}}